Old Web
English
Sign In
Acemap
>
Paper
>
P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
P3.01-073 TPX-0005 with an EGFR Tyrosine Kinase Inhibitor (TKI) Overcomes Innate Resistance in EGFR Mutant NSCLC
2017
R. Rosell
N. Karachaliou
J J Cui
Imane Chaib
Jordi Berenguer
J. Bratch
Xuesong Li
Jie Yang
Ana Drozdowskyj
C. Codony Servat
J. Codony Servat
Ana Giménez-Capitán
Santiago Viteri
M. Molina-Vila
Guillermo Lopez-Vivanco
A. Vergnenegre
J. M. Sánchez Torres
Mariano Provencio
F. De Marinis
Antonio Passaro
Enric Carcereny
N. Reguart
R. García Campelo
S. Ignatius Ou
Andrés F. Cardona
Peng Cao
Keywords:
General surgery
Cancer research
Tyrosine-kinase inhibitor
Mutant
Medicine
egfr tyrosine kinase
Pathology
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI
[]